Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01650870 · ClinicalTrials.gov registry record · Phase 2

Safety, Efficacy, and Patient Preference of Split-Dose Crystalline Lactulose as a Preparation for Colonoscopy in Adults

A Phase 2 study of Colonoscopy, sponsored by Benaroya Research Institute.

Completed
Registry status
Phase 2
Development phase
40
Enrollment target
1
Study location

NCT01650870: Completed Phase 2 study of Colonoscopy, sponsored by Benaroya Research Institute.

NCT01650870 is a Phase 2 study of Colonoscopy that has completed, run by Benaroya Research Institute. The registered enrollment target is 40 participants, below the 500-participant average among 20 other Colonoscopy trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01650870, a Phase 2 study of Colonoscopy, has completed, sponsored by Benaroya Research Institute.

COMPLETED
Registry status
Phase 2
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the efficacy of a split-dose regimen of crystalline lactulose for cleansing of the colon as a preparation for colonoscopy, as assessed by the physician's determination of the cleanliness of the colon using the Boston Bowel Prep Scale (BBPS).

Primary Outcome

To evaluate the primary objective of efficacy of the split-dose, the following endpoint will be measured: o Physician's determination of the cleanliness of the colon will be evaluated by completion of the Boston bowel prep scale.

Conditions Studied

Interventions

  • DRUG Crystalline Lactulose

Study Locations (1)

Washington

  • Virginia Mason Medical Center - Seattle

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2012-07
Est. Completion 2012-09
Phase Phase 2
Benaroya Research Institute

28 total trials

What the finished NCT01650870 record still lists

NCT01650870 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 500-participant average among 20 other Colonoscopy trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Colonoscopy appearing as the primary indexed condition, and to 1 intervention - of which Crystalline Lactulose is the first listed.

NCT01650870 reports a single indexed study location in Washington.

Frequently Asked Questions

What is clinical trial NCT01650870 about?

NCT01650870 is a clinical study titled "Safety, Efficacy, and Patient Preference of Split-Dose Crystalline Lactulose as a Preparation for Colonoscopy in Adults". The purpose of this study is to determine the efficacy of a split-dose regimen of crystalline lactulose for cleansing of the colon as a preparation for colonoscopy, as assessed by the physician's determination of the cleanliness of the colon using the Boston Bowel Prep Scale (BBPS).

What is the current status of trial NCT01650870?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2012-07. Estimated completion is 2012-09.

What conditions does trial NCT01650870 study?

This clinical trial studies the following conditions: Colonoscopy.

What interventions are being tested in trial NCT01650870?

The interventions under investigation include: Crystalline Lactulose (DRUG).

Who is sponsoring clinical trial NCT01650870?

This trial is sponsored by Benaroya Research Institute, which has 28 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01650870 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Colonoscopy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01650870's enrollment target sits among peer trials

40 21st of 20 the lowest of 20 other Colonoscopy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Colonoscopy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01650870, the US trial registry maintained by the National Library of Medicine. NCT01650870 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.